6-K - Alterity Therapeutics Limited | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Alterity Therapeutics appointed Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, effective March 2026. Dr. Claassen, a neurology professor at Vanderbilt University Medical Center and expert in neurodegenerative diseases including MSA, previously served as coordinating investigator for the Company's Phase 2 ATH434 study and will guide the Phase 3 trial.

Key Takeaways

1Daniel O. Claassen, M.D., M.S. appointed Chief Medical Advisor effective March 2026

2Dr. Claassen retains tenured professor role at Vanderbilt University Medical Center

3Served as coordinating investigator for ATH434 Phase 2 study in MSA

4Will guide ATH434 into Phase 3 pivotal trial

5Expert in movement disorders with over two decades of clinical and research experience

6ATH434 showed clinically meaningful slowing of MSA progression in Phase 2

Current Report Details

Event Type

6-K

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Other Event

Executive & Director Changes

Daniel O. Claassen, M.D., M.S.

Chief Medical Advisor

Appointed

Effective: 2026-03

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

ATH - DR DANIEL CLAASSEN AS CHIEF MEDICAL ADVISOR